These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9850479)

  • 1. The economic impact of diabetes.
    Jönsson B
    Diabetes Care; 1998 Dec; 21 Suppl 3():C7-10. PubMed ID: 9850479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Costs of Diabetes in the U.S. in 2017.
    American Diabetes Association
    Diabetes Care; 2018 May; 41(5):917-928. PubMed ID: 29567642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association
    Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic costs of diabetes in the U.S. in 2012.
    American Diabetes Association
    Diabetes Care; 2013 Apr; 36(4):1033-46. PubMed ID: 23468086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The costs of diabetes among Australians aged 45-64 years from 2015 to 2030: projections of lost productive life years (PLYs), lost personal income, lost taxation revenue, extra welfare payments and lost gross domestic product from Health&WealthMOD2030.
    Schofield D; Shrestha RN; Cunich MM; Passey ME; Veerman L; Tanton R; Kelly SJ
    BMJ Open; 2017 Jan; 7(1):e013158. PubMed ID: 28069621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of diabetes on workforce participation: results from a national household sample.
    Vijan S; Hayward RA; Langa KM
    Health Serv Res; 2004 Dec; 39(6 Pt 1):1653-69. PubMed ID: 15533180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost of diabetes in Latin America and the Caribbean.
    Barceló A; Aedo C; Rajpathak S; Robles S
    Bull World Health Organ; 2003; 81(1):19-27. PubMed ID: 12640472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of diabetes in Latin America and the Caribbean in 2015: Evidence for decision and policy makers.
    Barcelo A; Arredondo A; Gordillo-Tobar A; Segovia J; Qiang A
    J Glob Health; 2017 Dec; 7(2):020410. PubMed ID: 29163935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic value of disability-adjusted life years lost to violence: estimates for WHO Member States.
    Brown DW
    Rev Panam Salud Publica; 2008 Sep; 24(3):203-9. PubMed ID: 19115548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the burden of diabetes in Poland].
    Kissimova-Skarbek K; Pach D; Płaczkiewicz E; Szurkowska M; Szybiński Z
    Pol Arch Med Wewn; 2001 Sep; 106(3):867-73. PubMed ID: 11928598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach.
    Marcellusi A; Viti R; Mecozzi A; Mennini FS
    Eur J Health Econ; 2016 Mar; 17(2):139-47. PubMed ID: 25427540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Costs Attributable to Diabetes in Each U.S. State.
    Shrestha SS; Honeycutt AA; Yang W; Zhang P; Khavjou OA; Poehler DC; Neuwahl SJ; Hoerger TJ
    Diabetes Care; 2018 Dec; 41(12):2526-2534. PubMed ID: 30305349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes--the cost of illness and the cost of control. An estimate for Sweden 1978.
    Jönsson B
    Acta Med Scand Suppl; 1983; 671():19-27. PubMed ID: 6576620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association.
    Diabetes Care; 1998 Feb; 21(2):296-309. PubMed ID: 9539999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach.
    de Lagasnerie G; Aguadé AS; Denis P; Fagot-Campagna A; Gastaldi-Menager C
    Eur J Health Econ; 2018 Mar; 19(2):189-201. PubMed ID: 28190188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic burden of diabetes.
    Dall TM; Zhang Y; Chen YJ; Quick WW; Yang WG; Fogli J
    Health Aff (Millwood); 2010 Feb; 29(2):297-303. PubMed ID: 20075080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of urgency urinary incontinence in the United States: a systematic review.
    Coyne KS; Wein A; Nicholson S; Kvasz M; Chen CI; Milsom I
    J Manag Care Pharm; 2014 Feb; 20(2):130-40. PubMed ID: 24456314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct, indirect and intangible costs of acute hand and wrist injuries: A systematic review.
    Robinson LS; Sarkies M; Brown T; O'Brien L
    Injury; 2016 Dec; 47(12):2614-2626. PubMed ID: 27751502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.
    Örmeci N; Malhan S; Balık İ; Ergör G; Razavi H; Robbins S
    Hepatol Int; 2017 Nov; 11(6):509-516. PubMed ID: 29027109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.